Ar­cutis show­cas­es pos­i­tive PhI­II da­ta show­ing its top­i­cal cream scratched the sweet spot Ote­zla or steroids could­n't

The goal at Ar­cutis Bio­ther­a­peu­tics $AR­QT had been clear and straight­for­ward from day 1: to prove that it can take ex­ist­ing com­pounds against well es­tab­lished der­ma­tol­ogy tar­gets and make re­for­mu­la­tions that hit a sweet spot not yet scratched by any of its myr­i­ad block­buster, gener­ic or ex­per­i­men­tal ri­vals.

The first proof came Mon­day in the form of pos­i­tive topline re­sults from a pair of piv­otal Phase III tri­als. In­vestors re­act­ed cheer­ful­ly, send­ing the stock up 28.14% to $34.97.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.